文献速递垂体与肾上腺疾病性腺与生殖内分泌

Crinecerfont(一种CRF1受体拮抗剂)降低青少年先天性肾上腺皮质增生症患者的肾上腺雄激素

Crinecerfont, a CRF1 Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal Hyperplasia.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

这项在美国4个中心开展的开放标签2期研究(NCT04045145)纳入8例14至17岁经典21-羟化酶缺乏症先天性肾上腺皮质增生症青少年,口服Crinecerfont 50 mg每日两次共14天。第14天促肾上腺皮质激素中位降幅57%、17-羟孕酮降幅69%、雄烯二酮降幅58%;女性中60%(3/5)睾酮较基线下降≥50%。

要点

  • 8例经典21-羟化酶缺乏症青少年口服Crinecerfont 50 mg每日两次共14天。
  • 第14天促肾上腺皮质激素中位下降57%、17-羟孕酮下降69%、雄烯二酮下降58%。
  • 女性中60%(3/5)睾酮较基线下降≥50%。

核心结论

  • 经典21-羟化酶缺乏症先天性肾上腺皮质增生症青少年口服Crinecerfont 14天后肾上腺雄激素及雄激素前体大幅下降,结果与成人研究一致。

研究设计与样本

  • 开放标签2期研究(NCT04045145),在美国4个中心开展。
  • 纳入8例14至17岁经典21-羟化酶缺乏症先天性肾上腺皮质增生症男性与女性患者。
  • Crinecerfont口服50 mg每日两次,随早晚餐服用,连续14天。

主要发现

  • 8例受试者(3例男性、5例女性)入组,中位年龄15岁,88%为白人。
  • 第14天促肾上腺皮质激素中位较基线下降57%。
  • 第14天17-羟孕酮中位较基线下降69%。
  • 第14天雄烯二酮中位较基线下降58%。
  • 女性受试者中60%(3/5)睾酮较基线下降≥50%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Crinecerfont, a corticotropin-releasing factor type 1 receptor antagonist, has been shown to reduce elevated adrenal androgens and precursors in adults with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD), a rare autosomal recessive disorder characterized by cortisol deficiency and androgen excess due to elevated adrenocorticotropin. OBJECTIVE: To evaluate the safety, tolerability, and efficacy of crinecerfont in adolescents with 21OHD CAH. METHODS: This was an open-label, phase 2 study (NCT04045145) at 4 centers in the United States. Participants were males and females, 14 to 17 years of age, with classic 21OHD CAH. Crinecerfont was administered orally (50 mg twice daily) for 14 consecutive days with morning and evening meals. The main outcomes were change from baseline to day 14 in circulating concentrations of ACTH, 17-hydroxyprogesterone (17OHP), androstenedione, and testosterone. RESULTS: 8 participants (3 males, 5 females) were enrolled; median age was 15 years and 88% were Caucasian/White. After 14 days of crinecerfont, median percent reductions from baseline to day 14 were as follows: ACTH, -57%; 17OHP, -69%; and androstenedione, -58%. In female participants, 60% (3/5) had ≥50% reduction from baseline in testosterone. CONCLUSION: Adolescents with classic 21OHD CAH had substantial reductions in adrenal androgens and androgen precursors after 14 days of oral crinecerfont administration. These results are consistent with a study of crinecerfont in adults with classic 21OHD CAH.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Newfield RS, Sarafoglou K, Fechner PY, et al. Crinecerfont, a CRF1 Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab. 2023. PMID: 37216921. doi:10.1210/clinem/dgad270

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。